School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin, China.
Chem Biol Drug Des. 2023 Sep;102(3):547-556. doi: 10.1111/cbdd.14272. Epub 2023 May 30.
α-glucosidase inhibitors (AGIs) were commonly used in clinical for the treatment of type 2 diabetes. Xanthones were naturally occurring antioxidants, and they may also be potential AGIs. In this study, eleven 1,6- and 1,3-substituted xanthone compounds were designed and synthesized, of which four were new compounds. Their α-glucosidase inhibitory activities in vitro and in silico were evaluated. Five xanthone compounds with higher activity than acarbose were screened out, and the xanthones substituted at the 1,6-positions were more likely to be potential α-glucosidase non-competitive inhibitors. The binding mode of xanthones with α-glucosidase was further studied by molecular docking method, and the results showed that the inhibitory effect of non-competitive inhibitors on site 1 of α-glucosidase may be related to the hydrogen bonds formed by the compounds with amino acid residues ASN165, HIS209, TRY207, ASP243, and SER104. This study provided a theoretical basis of the rapid discovery and structural modification of non-competitive xanthone inhibitors of α-glucosidase.
α-葡萄糖苷酶抑制剂(AGIs)常用于临床治疗 2 型糖尿病。黄烷酮是天然存在的抗氧化剂,它们也可能是潜在的 AGIs。在这项研究中,设计并合成了 11 种 1,6-和 1,3-取代的黄烷酮化合物,其中 4 种是新化合物。评估了它们在体外和体内的α-葡萄糖苷酶抑制活性。筛选出了 5 种比阿卡波糖活性更高的黄烷酮化合物,并且在 1,6-位取代的黄烷酮更有可能成为潜在的α-葡萄糖苷酶非竞争性抑制剂。进一步通过分子对接方法研究了黄烷酮与α-葡萄糖苷酶的结合模式,结果表明,非竞争性抑制剂对α-葡萄糖苷酶位点 1 的抑制作用可能与化合物与氨基酸残基 ASN165、HIS209、TRY207、ASP243 和 SER104 形成氢键有关。本研究为快速发现和结构修饰非竞争性黄烷酮α-葡萄糖苷酶抑制剂提供了理论依据。